SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results.
Related Questions
What were the drivers behind any changes in gross margin and operating expense trends?
What was the reported revenue and how does it compare to consensus estimates?
Did the company beat or miss earnings per share expectations for Q2 2025?
What was the net profit or loss and how does it compare year‑over‑year?
How does the company’s valuation metrics (P/E, EV/EBITDA, price‑to‑sales) compare to other fertility‑clinic operators?
What guidance did INVO provide for FY 2025 and FY 2026 regarding revenue, EBITDA, and cash flow?
Are there any new clinic acquisitions, expansions, or partnerships disclosed that could affect future growth?
What is the company’s cash position, debt level, and cash‑burn rate after the quarter?
What does management say about the pipeline of new fertility technologies or services?
How does this quarter’s performance compare to the prior quarter and the same quarter last year?
What impact might this earnings release have on the stock price in the short‑term versus the long‑term?
What risks or uncertainties did management highlight that could affect future performance?